The Food and Drug Administration (FDA) is set to hold a meeting in July to review easing restrictions on more than half a dozen peptides, which are unapproved therapies that have gained popularity among wellness influencers and celebrities. This consideration follows repeated pledges from Health Secretary Robert F. Kennedy Jr. to loosen regulations on these substances, which are often promoted for muscle building, injury healing, and anti-aging, despite limited research supporting these claims and most not having undergone FDA safety review.
The agency will ask an advisory panel to determine if seven specific peptides should be added to a list of substances that can be safely produced by compounding pharmacies. These include BPC-157, marketed for injury healing and inflammation reduction, TB-500 for wound healing, and MOTS-c for obesity. The FDA also indicated it would soon remove these chemicals from a restrictive list previously reserved for unapproved, high-risk drugs.
This marks a shift from the Biden administration, which had added nearly $20 billion worth of peptides to a federal list of substances unsuitable for compounding pharmacies due to significant safety risks like cancer, and liver, kidney, or heart problems. The current FDA's Pharmacy Compounding Advisory Committee (PCAC), which is currently understaffed, has historically required extensive clinical trials to prove safety and effectiveness before making affirmative recommendations, which are largely absent for these peptides. Concerns have been raised by critics, including Bloomberg columnist Lisa Jarvis, that this move, championed by Secretary Kennedy, does not adequately address the need for proven safety and efficacy, potentially making unproven and unsafe products more widely available.
While some peptides have been FDA-approved for specific conditions, many promoted online lack approval, making their marketing as drugs illegal. BPC-157 and TB-500 are even banned by international sports authorities as doping substances. The move to shift demand away from a "dangerous black market" is a stated goal, but critics question if making these substances more accessible without robust data is the right approach. The compounding industry and some dietary supplement makers are pushing for expanded use and federal definitions to include peptides in their products.
